Gastrointestinal Cancers: mCRC (Issue 7)

Neoadjuvant therapy has become increasingly plausible for patients with advanced pancreatic cancer, as the quantity and quality of approved therapies continue to increase, according to Colin Weekes, MD, PhD.

A potential biomarker to guide the treatment of patients with metastatic colorectal cancer (mCRC) failed to stratify patients by progression-free survival (PFS) or responsiveness to bevacizumab, according to a randomized trial.

Complimenting best supporting care with panitumumab dropped the risk of death by 30% for patients with RAS wild-type chemorefractory metastatic colorectal cancer (mCRC).

Van Loon says that oncologists need further research into how often and for how long patients with gastrointestinal cancers should be monitored.

Treatments can be better customized and tailored based on each patient's individual desires and characteristics, now that two effective options are available for refractory metastatic colorectal cancer, according to Jennifer Wu, MD.

The trial looked at radionuclide therapy Lu-Dotatate in patients with advanced midgut neuroendocrine tumors (NETs), and showed an improvement in overall survival and the reduction of progression or death risk by 79%.

Shah says as more treatments become available, oncologists need to consider the order in which they give treatments to patients with gastric and gastroesophageal junction cancer.

Marginal improvements were seen in clinical outcomes for patients with metastatic colorectal cancer (CRC) treated with FOLFOXIRI plus bevacizumab compared with FOLFOX plus bevacizumab; however, these findings were inconsistent, according to results from the phase II STEAM trial.